1. Search Result
Search Result
Results for "

diabetic renal dysfunction

" in MedChemExpress (MCE) Product Catalog:

4

Inhibitors & Agonists

2

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N10423

    (-)-Cubebin

    Cholinesterase (ChE) Bacterial Fungal Parasite p38 MAPK Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Cubebin ((-)-Cubebin), a dibenzyl butyrolactone lignan, is an orally active AChE inhibitor. Cubebin binds to active sites of NF-κB, TNF-α, and TGF-β1 via hydrogen and hydrophobic interactions, obstructing critical residues to inhibit pro-inflammatory or renal fibrosis-related activity. Cubebin enhances p38 MAPK phosphorylation to increase tyrosinase gene expression, stimulating melanogenesis via elevated tyrosinase activity, expression, and mRNA levels. Cubebin reduces oxidative stress via enhanced endogenous antioxidant enzyme activity and inhibited lipid peroxidation, regulates lipid metabolism, improves glycemic control, and exerts renoprotective effects via reduced renal dysfunction markers and improved renal architecture. Cubebin shows antimicrobial activity. Cubebin exerts larvicidal activity against Angiostrongylus cantonensis larvae, with no cytotoxicity toward monkey or human cell lines or Caenorhabditis elegans. Cubebin can be used for the research of diabetic nephropathy, melanoma, colon adenocarcinoma, neuroangiostrongyliasis, Alzheimer’s disease (AD) and depression .
    Cubebin
  • HY-179041

    PGE synthase Prostaglandin Receptor MDM-2/p53 Amino acid Transporter Glutathione Peroxidase Ferroptosis Metabolic Disease Endocrinology
    SZ0232 is a selective mPGES-2 inhibitor. SZ0232 binds to the active site of mPGES-2 via hydrogen bonds and π-π stacking, reduces the production of prostaglandin E2 (PGE2) and blocks the PGE2-EP3 pathway. SZ0232 regulates Ferroptosis by activating the heme-dependent p53/SLC7A11/GPX4 axis, inhibits lipid peroxidation, and protects renal tubules. SZ0232 enhances glucose-stimulated insulin secretion, inhibits β-cell senescence, and improves glucose homeostasis. SZ0232 reduces renal lipid accumulation, alleviates fibrosis, and ameliorates renal dysfunction in diabetic mice. SZ0232 inhibits renal cyst growth in polycystic kidney disease models. SZ0232 exhibits an insulinotropic effect that strengthens with the increase of animal age. SZ0232 can be used in studies related to type 2 diabetes, acute kidney injury, diabetic kidney disease, and autosomal dominant polycystic kidney disease .
    SZ0232
  • HY-106661

    Amyloid-β Neurological Disease Metabolic Disease
    GLY-230 is an orally active compound. GLY-230 can inhibit nonenzymatic glycation and reduce glycated albumin. GLY-230 can reduce brain Aβ42 levels. GLY-230 can be used for the researches of metabolic and neurological disease, such as diabetic renal dysfunction .
    GLY-230
  • HY-N18656

    Bacterial Infection
    Terminalia chebula extract, derived from the fruit of the Terminalia chebula tree. Rich in bioactive compounds such as tannins, flavonoids, phenols, and organic acids like gallic acid and ellagic acid, this extract demonstrates a wide range of pharmacological activities. It acts as a natural laxative, supports digestive health, and exhibits potent antioxidant, anti-inflammatory, and antibacterial properties, effectively targeting various pathogenic bacteria, including Helicobacter pylori, Staphylococcus aureus, and Escherichia coli. Terminalia Chebula Extract also shows significant hepatoprotective effects, shielding the liver from damage through antioxidant and anti-inflammatory mechanisms. It has nephroprotective properties, alleviating renal dysfunction and enhancing kidney health by modulating inflammatory pathways. Additionally, the extract demonstrates neuroprotective activity, reducing neuronal damage and improving memory function. It has potential anti-diabetic effects, enhancing glucose uptake and reducing oxidative stress.
    Terminalia chebula extract

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: